Selank Peptide: Anxiolytic Nootropic From Tuftsin

Selank (TP-7) is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and a molecular weight of 751.9 Da. Developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences, it was engineered by extending the naturally occurring immune peptide tuftsin with a C-terminal Pro-Gly-Pro tripeptide to dramatically improve metabolic stability. The result is a compound that crosses into the central nervous system within minutes of intranasal administration and exerts anxiolytic, nootropic, and immunomodulatory effects through several distinct neurochemical pathways, without the sedation, cognitive impairment, or dependence that characterize benzodiazepines.

Primary areas of research include:

• Anxiolytic therapy for generalized anxiety disorder and neurasthenia
• Cognitive enhancement and neuroprotection via BDNF upregulation
• Immune modulation through cytokine and interferon regulation
• Stabilization of enkephalin systems under stress conditions
• Adjunctive treatment for anxiety-depressive disorders

What Is Selank?

Selank is a synthetic analog of tuftsin, a tetrapeptide (Thr-Lys-Pro-Arg) that occurs naturally in the human body as a cleavage product of the Fc region of immunoglobulin G (IgG). Tuftsin was first identified in the 1970s and is primarily known for its role in innate immunity. It enhances the phagocytic activity of macrophages and neutrophils. However, tuftsin itself proved impractical as a therapeutic agent due to rapid enzymatic degradation, with a plasma half-life measured in seconds.

In the 1990s, a research team led by Nikolai Myasoedov at the Institute of Molecular Genetics of the Russian Academy of Sciences, in collaboration with the V.V. Zakusov Research Institute of Pharmacology, set out to create a metabolically stable version of tuftsin that could serve as a therapeutic agent for anxiety disorders. By appending the tripeptide sequence Pro-Gly-Pro to tuftsin's C-terminus, they created Selank, a heptapeptide that retained tuftsin's immunomodulatory properties while gaining pronounced neurotropic effects and substantially improved resistance to enzymatic degradation.

Selank was approved by the Russian Federation Ministry of Health in 2009 and is available by prescription in Russia under the brand name Selanc, and is also reportedly available in Ukraine. It is marketed as a 0.15% nasal spray solution for the treatment of generalized anxiety disorder (GAD) and as an adjunctive treatment for neurasthenic conditions. In Russian clinical practice, it has been prescribed since the early 2010s, typically in 14-day treatment courses.

The compound's dual heritage, rooted in both immunology (tuftsin) and neuropsychopharmacology, gives it a pharmacological profile that is unusual among anxiolytics. It is neither a classical benzodiazepine nor a selective serotonin reuptake inhibitor, but a peptide that modulates multiple neurotransmitter systems simultaneously while preserving immune function.

How It Works

Selank's mechanism of action is multifaceted, involving at least four distinct neurochemical and immunological pathways. This polypharmacology likely explains both its broad therapeutic profile and its favorable side effect profile. Rather than saturating a single receptor system, Selank modulates several systems at moderate intensity.

GABAergic and Serotonergic Modulation

The most extensively studied mechanism of Selank involves its interaction with the GABAergic system. Research published in Frontiers in Pharmacology demonstrated that Selank administration rapidly alters the expression of genes involved in GABAergic neurotransmission, including genes encoding GABA-A receptor subunits. The peptide appears to allosterically modulate GABA-A receptors in a manner pharmacologically similar to benzodiazepines, enhancing inhibitory neurotransmission to reduce anxiety, but without directly binding the benzodiazepine site.

This distinction is critical. Classical benzodiazepines (diazepam, alprazolam, phenazepam) bind directly to a specific allosteric site on the GABA-A receptor, producing potent anxiolysis alongside sedation, muscle relaxation, cognitive impairment, tolerance development, and physical dependence. Selank's indirect modulation of the GABAergic system appears to produce anxiolysis without these accompanying effects. In a clinical comparison with phenazepam, Selank achieved comparable anxiety reduction without sedation, muscle relaxation, tolerance, or withdrawal syndrome.

Selank also modulates serotonergic pathways. In murine models where serotonin synthesis was experimentally reduced, Selank administration modulated serotonin metabolism in brainstem regions critical for mood regulation. This dual GABAergic-serotonergic activity may account for Selank's antidepressant effects observed alongside its primary anxiolytic action.

BDNF and Neuroplasticity

Brain-derived neurotrophic factor (BDNF) is a protein essential for neuronal survival, synaptic plasticity, and the formation of new neural connections. Reduced BDNF expression is implicated in depression, anxiety disorders, and cognitive decline. Experimental data from rodent models demonstrate that Selank increases BDNF mRNA expression in the hippocampus, a brain region central to memory processing and emotional regulation.

This BDNF upregulation is particularly significant under stress conditions. Chronic stress and elevated glucocorticoids suppress hippocampal BDNF expression, contributing to the cognitive impairment and emotional dysregulation seen in anxiety disorders. Selank's ability to counteract this stress-induced BDNF suppression provides a mechanistic explanation for its nootropic effects, improved memory, enhanced learning, and greater cognitive flexibility under pressure.

The neuroplasticity effects also have temporal implications. While Selank's GABAergic modulation produces rapid anxiolysis (within minutes of intranasal administration), BDNF-mediated neuroplastic changes develop over days to weeks of treatment, potentially explaining the progressive cognitive improvements observed during 14-day treatment courses.

Enkephalin System Effects

Enkephalins are endogenous opioid peptides that play central roles in mood regulation, stress response, and pain modulation. In patients with generalized anxiety disorder, research has documented decreased levels of leu-enkephalin, with the deficit correlating with disease duration and symptom severity.

Selank inhibits the enzymatic degradation of enkephalins by suppressing the activity of enkephalin-degrading enzymes. This prolongs the half-life and increases the availability of endogenous enkephalins, effectively boosting the body's own stress-buffering opioid system without introducing exogenous opioids. In the clinical trial comparing Selank to medazepam, Selank treatment produced measurable increases in leu-enkephalin levels that correlated with improvements in anxiety scores, a finding not observed with the benzodiazepine comparator.

This mechanism is distinct from and complementary to Selank's GABAergic effects. While GABA-A modulation provides rapid anxiolysis, enkephalin stabilization addresses the underlying neurochemical deficit associated with chronic anxiety, potentially contributing to more durable therapeutic effects.

Immune Modulation

Selank retains and extends the immunomodulatory properties of its parent peptide tuftsin. Research examining 84 inflammation-related genes found that Selank significantly altered the expression of 34 genes across functional groups including chemokines, chemokine receptors, cytokines, and cytokine receptors.

Key immunological findings include:

• Interferon-alpha induction: Selank administration induces expression of the IFN-alpha gene without affecting IL-4, IL-10, or TNF-alpha expression. This selective interferon induction suggests antiviral activity without broad inflammatory activation.
• IL-6 modulation: Selank influences interleukin-6 expression, a cytokine involved in both immune defense and neuroinflammation. The direction and magnitude of this effect appear context-dependent, potentially reflecting an immunomodulatory rather than immunostimulatory role.
• Phagocytic enhancement: Consistent with its tuftsin heritage, Selank enhances the phagocytic activity of monocytes and neutrophils, supporting innate immune surveillance.
• Th1/Th2 balance: Selank appears to influence the balance between Th1 and Th2 cytokine profiles, with implications for immune regulation in both infectious and autoimmune contexts.

This immune dimension distinguishes Selank from virtually all conventional anxiolytics, which either have no effect on immune function or suppress it. For individuals whose anxiety coexists with immune compromise or chronic infection, Selank's dual neurotropic-immunomodulatory profile is pharmacologically unique. For dedicated immune peptides, see Thymosin Alpha 1.

Administration

Selank is primarily administered intranasally, which distinguishes it from most peptides in the biohacking space that require subcutaneous injection. The intranasal route is not merely a convenience. It is pharmacologically optimal for Selank. Like Semax, Selank's small molecular size (seven amino acids) and rapid absorption kinetics allow efficient uptake across the nasal mucosa before the cavity's mucociliary clearance mechanism removes the compound — a window that larger, slower-absorbing peptides typically miss.

Intranasal Delivery (Preferred Route)

Intranasal administration exploits the olfactory and trigeminal nerve pathways to deliver Selank directly to the central nervous system, bypassing the blood-brain barrier. Pharmacokinetic studies in rats demonstrated that Selank is detectable in plasma within 30 seconds and in brain tissue within 2 minutes of intranasal administration. This rapid CNS delivery accounts for the onset of anxiolytic effects within minutes of dosing.

The Russian-approved formulation is a 0.15% solution in a metered-dose nasal spray device. Each spray delivers a calibrated dose, eliminating the need for reconstitution, sterile technique, or syringes. For users outside Russia, compounding pharmacies and research suppliers offer Selank in both pre-made nasal spray and lyophilized powder formats.

Intranasal technique:

1. Clear nasal passages before administration
2. Tilt head slightly forward
3. Insert spray nozzle into nostril, angling slightly away from the nasal septum
4. Administer one to two sprays per nostril
5. Breathe gently through the nose for 10 to 15 seconds after application
6. Avoid blowing the nose for several minutes post-administration

Subcutaneous Injection (Alternative)

When nasal spray formulations are unavailable, Selank can be administered subcutaneously. This route requires reconstitution of lyophilized powder with bacteriostatic water.

Reconstitution for subcutaneous use:

• Use a 1:1 ratio (e.g., 5 mg Selank + 5 mL bacteriostatic water = 1 mg/mL)
• Add water slowly along the vial wall; do not inject directly onto the powder
• Swirl gently until dissolved; do not shake
• Refrigerate reconstituted solution and use within 28 days

Subcutaneous bioavailability is adequate but lacks the rapid CNS delivery advantage of the intranasal route. Onset of effects is slower (15 to 30 minutes versus 2 to 5 minutes for intranasal).

Research Evidence

Selank's evidence base is unusual among peptides in the nootropic and anxiolytic space: it includes actual clinical trials in human patients, albeit conducted primarily within the Russian clinical research system. The compound also has an extensive preclinical dataset spanning anxiety, cognition, and immune function.

Clinical Trial: Selank vs. Medazepam in GAD

The foundational clinical study enrolled 62 patients with generalized anxiety disorder and neurasthenia, comparing Selank (30 patients) to the benzodiazepine medazepam (32 patients). Both drugs produced comparable anxiolytic effects as measured by the Hamilton Anxiety Rating Scale, Zung Self-Rating Anxiety Scale, and Clinical Global Impression scale. However, Selank additionally demonstrated antiasthenic and psychostimulant properties not seen with medazepam. Critically, Selank treatment correlated with increases in leu-enkephalin levels, a neurochemical change linked to improved anxiety scores and absent in the benzodiazepine group.

Clinical Trial: Selank vs. Phenazepam

A second clinical comparison evaluated Selank against phenazepam (a potent benzodiazepine widely prescribed in Russia) in patients with anxiety disorders. Selank again demonstrated comparable anxiolytic efficacy without the sedation, muscle relaxation, tolerance development, or withdrawal syndrome characteristic of phenazepam. This study strengthened the clinical case for Selank as a benzodiazepine alternative with a superior tolerability profile.

Preclinical: GABAergic Gene Expression

A 2016 study published in Frontiers in Pharmacology examined gene expression changes following Selank administration, finding significant alterations in genes encoding GABA-A receptor subunits and GABA transporters. These changes were rapid (detectable within hours), supporting the mechanism of allosteric GABA-A modulation. A follow-up study in IMR-32 neuroblastoma cells confirmed that Selank's effects on GABAergic gene expression were distinct from those produced by GABA itself or the antipsychotic olanzapine.

Preclinical: Synergy With Diazepam

Research published in Behavioural Neurology demonstrated that Selank enhanced the anxiolytic effects of diazepam in rats subjected to unpredictable chronic mild stress. The combination produced greater anxiety reduction than either compound alone, suggesting that Selank's mechanism is complementary to, rather than redundant with, classical benzodiazepine action.

Preclinical: Immune and Inflammatory Gene Expression

Studies examining Selank's effects on inflammation-related gene expression in mouse spleen tissue found significant changes in 34 of 84 genes analyzed, spanning chemokines, cytokines, and their receptors. A temporal dynamics study revealed that these gene expression changes followed a biphasic pattern, with early pro-inflammatory gene activation followed by later anti-inflammatory gene upregulation, consistent with an immunomodulatory rather than immunosuppressive profile.

Limitations of the Evidence Base

The honest assessment of Selank's evidence is that it is stronger than most peptides in the nootropic space but weaker than established Western pharmaceuticals for anxiety. Key limitations include: clinical trials were conducted in Russia with limited sample sizes and have not been independently replicated in Western research settings; most published studies are in Russian-language journals with limited international peer review; long-term safety data beyond 14-day courses is sparse; and placebo-controlled, double-blind methodology is not consistently documented across all studies.

Stacking

Selank's multi-target mechanism makes it a logical candidate for combination with compounds that address complementary pathways. The most established combination is with Semax, its sister peptide from the same Russian research program.

Selank + Semax

The most commonly discussed stack in the nootropic community. Selank provides anxiolytic stabilization through GABAergic and enkephalin pathways; Semax provides cognitive stimulation through dopaminergic activation and BDNF upregulation. For a detailed comparison of both peptides, see Selank vs Semax. Together, they create a balanced profile of enhanced focus without anxiety, calm alertness rather than jittery stimulation or sedated calm. Both are administered intranasally on compatible schedules. Russian clinicians have reportedly used this combination, though formal combination studies are limited.

Selank + Noopept

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic nootropic that also modulates BDNF and NGF expression. Combined with Selank, the rationale is additive neurotrophin support plus anxiolysis. Both can be administered intranasally.

Selank + Magnesium L-Threonate

Magnesium L-threonate crosses the blood-brain barrier and enhances GABAergic function through a different mechanism than Selank (direct NMDA receptor modulation). The combination may provide complementary anxiolytic support through convergent but distinct pathways.

Selank + Adaptogens (Ashwagandha, Rhodiola)

Herbal adaptogens that modulate the hypothalamic-pituitary-adrenal axis may complement Selank's neurotransmitter-level anxiolysis by reducing upstream cortisol signaling. No formal interaction studies exist.

General Stacking Caution: Formal drug interaction data for Selank is effectively nonexistent outside of the diazepam synergy study. Establishing individual response to Selank alone before introducing additional compounds is advisable.

Side Effects

Selank has one of the cleanest side effect profiles of any anxiolytic compound studied in clinical settings. This tolerability advantage over benzodiazepines and SSRIs is consistently highlighted across Russian clinical literature.

Commonly Reported (Intranasal):

• Mild stinging or irritation in nasal passages (transient, resolves within minutes)
• Nasal dryness with repeated daily use
• Mild taste or odor disturbance immediately after administration

Uncommonly Reported:

• Headache (mild, typically with higher doses)
• Dizziness (transient)
• Fatigue (paradoxical, reported rarely)

Notably Absent:

• Sedation or drowsiness (consistently absent across clinical comparisons)
• Cognitive impairment or psychomotor slowing
• Tolerance development within standard 14-day courses
• Physical dependence or withdrawal symptoms upon cessation
• Rebound anxiety after treatment discontinuation
• Muscle relaxation or ataxia

Serious Adverse Events: No serious adverse events have been attributed to Selank in published clinical literature. The FDA has raised a general immunogenicity concern regarding compounded peptide products, the theoretical risk that the body could mount an immune response against the peptide, but no cases of immunogenicity-related adverse events from Selank have been published.

Sourcing Risks: As with all unregulated peptides, individuals sourcing Selank from research chemical suppliers face contamination, degradation, and mislabeling risks that are distinct from the compound's intrinsic safety profile. Third-party certificate of analysis verification is essential.

Legal Status / FDA

Selank occupies distinctly different regulatory positions depending on jurisdiction. For a full overview of where research peptides stand legally, see the peptide legality guide.

Russia:

• Approved prescription medication since 2009
• Marketed as Selanc nasal spray (0.15% solution)
• Indicated for generalized anxiety disorder and neurasthenic conditions
• Available through pharmacies with a physician's prescription

United States:

• Not FDA-approved for any indication
• Not classified as a controlled substance (not DEA-scheduled)
• In September 2024, Selank acetate (TP-7) was removed from the FDA's Category 2 bulk drug substances list because the nominators withdrew their nominations, not because the FDA cleared it for safety
• Status for compounding use under Section 503A/503B of the Federal Food, Drug, and Cosmetic Act remains under review pending Pharmacy Compounding Advisory Committee evaluation
• Cannot legally be marketed as a drug, food, or dietary supplement with therapeutic claims
• Available as a research chemical from unregulated suppliers

European Union, United Kingdom, Canada, Australia:

• Not approved by the EMA, MHRA, Health Canada, or TGA
• Exists in a regulatory gray area as a research compound
• Importation for personal use varies by jurisdiction and is subject to customs enforcement

The regulatory asymmetry between Russia (where Selank is an established pharmaceutical) and Western countries (where it remains unapproved) reflects differences in clinical trial standards and regulatory pathways rather than any specific safety finding that has prevented approval. No Western regulatory authority has rejected Selank based on safety concerns. The compound simply has not been submitted for approval outside Russia.

Sports / WADA

Selank is not explicitly named on the 2026 World Anti-Doping Agency Prohibited List. However, athletes subject to anti-doping testing should exercise significant caution.

WADA's S0 category prohibits "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use." Because Selank is not approved by the FDA, EMA, or other major Western regulatory authorities, it could be classified as a prohibited non-approved substance under S0, even though it is approved in Russia.

The interpretation of S0 in cases where a substance has regulatory approval in one country but not in the testing athlete's jurisdiction has not been definitively resolved in published anti-doping jurisprudence for Selank specifically. Athletes should:

• Consult their sport's anti-doping authority before using Selank
• Be aware that S0 is intentionally broad and catch-all
• Understand that "not explicitly banned" does not equal "permitted"
• Consider that testing methodologies for peptides continue to evolve

Selank vs. Semax

Because both Selank and Semax emerged from the same Russian peptide research program, are administered intranasally, and are frequently discussed together, a direct comparison is warranted.

Selank is derived from tuftsin (an IgG fragment) with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its primary action is anxiolytic and immunomodulatory, working through GABAergic, serotonergic, and enkephalin pathways. Both Selank and Semax are featured in the best peptides for cognitive enhancement guide. Subjectively, users describe calm focus and reduced anxiety. It was approved in Russia as an anxiolytic in 2009, is administered intranasally at 200 to 400 mcg two to three times daily, and its main side effect is mild nasal irritation. It is best suited for anxiety reduction with cognitive preservation.

Semax is derived from ACTH(4-7) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its primary action is nootropic and neuroprotective, working through dopaminergic, BDNF, and melanocortin pathways. Subjectively, users describe sharpened cognition and mental energy. It was listed on Russia's ZHVLP as a nootropic/neuroprotectant in 2011, is administered intranasally at 200 to 600 mcg two to three times daily, and its side effects include nasal irritation and potential glucose changes. It is best suited for cognitive enhancement and focus.

Selank is the stabilizer, it maintains cognitive function under stress by reducing anxiety. Semax is the accelerator, it pushes cognitive function forward with mild stimulation. Many users combine both for a balanced nootropic-anxiolytic profile, administering Selank and Semax at alternating intervals throughout the day.

Variants

N-Acetyl Selank Amidate

N-Acetyl Selank Amidate is a chemically modified form of Selank with an acetyl group on the N-terminus and an amide group on the C-terminus. These modifications protect the peptide from exopeptidase degradation at both ends of the molecule, resulting in enhanced metabolic stability, improved blood-brain barrier penetration, and a longer effective half-life (estimated at 4 to 6 hours compared to standard Selank's rapid parent-compound degradation). Bioavailability is reported to be 30% to 50% higher than standard Selank, allowing lower effective doses. N-Acetyl Selank Amidate is not an approved pharmaceutical in any jurisdiction and is available only as a research compound.

Reconstitution, Storage and Prep

Pre-Made Nasal Spray (No Reconstitution Required): If obtained as a pre-made nasal spray solution (as marketed in Russia), no preparation is needed. Store at 2 to 8 degrees Celsius (refrigerator) and use within the timeframe specified by the manufacturer (typically 30 days after opening).

Lyophilized Powder (Requires Reconstitution):

1. Allow the vial to reach room temperature
2. Use bacteriostatic water (0.9% benzyl alcohol) as the reconstitution vehicle
3. Draw the appropriate volume into an insulin syringe
4. Insert the needle and inject water slowly along the interior vial wall
5. Swirl gently until fully dissolved; do not shake
6. Solution should be clear and colorless

Common Reconstitution Ratio:

• 5 mg Selank + 5 mL bacteriostatic water = 1 mg/mL
• For nasal spray: transfer reconstituted solution to a sterile metered-dose nasal spray bottle

Storage Guidelines:

• Lyophilized powder: Store at -20 degrees Celsius for long-term; stable at 2 to 8 degrees Celsius for several months
• Protect from light and moisture
• Reconstituted solution: Store at 2 to 8 degrees Celsius; use within 28 days
• Discard if solution becomes cloudy, discolored, or contains particles

Conclusion

Selank occupies a distinctive position in the peptide landscape: it is one of the few nootropic or anxiolytic peptides that has crossed the threshold from preclinical research into regulatory approval and clinical prescription, even if that approval is limited to Russia. Its dual origin from tuftsin gives it a pharmacological profile that no Western anxiolytic replicates: genuine GABA-mediated anxiety reduction combined with immune modulation, enkephalin stabilization, and BDNF-driven neuroplasticity, delivered through a non-invasive intranasal route.

The clinical evidence, while compelling, comes with real caveats. The trials were conducted in Russia with sample sizes that would not meet Western Phase 3 standards, most primary publications are in Russian-language journals, and independent replication in Western clinical settings has not occurred. This does not invalidate the findings, but it does mean that the level of certainty is lower than for pharmaceuticals that have survived the FDA or EMA approval gauntlet.

For individuals managing anxiety who are exploring peptide-based options, Selank offers a pharmacologically rational alternative to benzodiazepines, one with a mechanism that addresses anxiety through multiple complementary pathways without the sedation, cognitive impairment, or dependence risk that makes long-term benzodiazepine use problematic. Its intranasal administration is genuinely convenient, its side effect profile is remarkably clean, and its combination potential with Semax is well-established in the nootropic community.

The appropriate stance toward Selank is the same as toward any compound with promising but geographically limited clinical evidence: informed interest balanced with clear-eyed recognition of what remains unproven in rigorous, large-scale, Western clinical frameworks.